PL2801625T3 - Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków - Google Patents
Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i lekówInfo
- Publication number
- PL2801625T3 PL2801625T3 PL14173142T PL14173142T PL2801625T3 PL 2801625 T3 PL2801625 T3 PL 2801625T3 PL 14173142 T PL14173142 T PL 14173142T PL 14173142 T PL14173142 T PL 14173142T PL 2801625 T3 PL2801625 T3 PL 2801625T3
- Authority
- PL
- Poland
- Prior art keywords
- diagnosis
- alcohol
- treatment
- molecular genetic
- drug dependence
- Prior art date
Links
- 208000007848 Alcoholism Diseases 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title 1
- 201000007930 alcohol dependence Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 206010013663 drug dependence Diseases 0.000 title 1
- 230000002068 genetic effect Effects 0.000 title 1
- 208000011117 substance-related disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Addiction (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36120310P | 2010-07-02 | 2010-07-02 | |
| US201161429416P | 2011-01-03 | 2011-01-03 | |
| US201161488328P | 2011-05-20 | 2011-05-20 | |
| EP14173142.2A EP2801625B1 (en) | 2010-07-02 | 2011-07-01 | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
| EP11801503.1A EP2588630A4 (en) | 2010-07-02 | 2011-07-01 | MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL AND MEDICINE DEPENDENCE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2801625T3 true PL2801625T3 (pl) | 2018-06-29 |
Family
ID=45402467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14173142T PL2801625T3 (pl) | 2010-07-02 | 2011-07-01 | Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków |
Country Status (17)
| Country | Link |
|---|---|
| US (9) | US8753815B2 (pl) |
| EP (2) | EP2588630A4 (pl) |
| AU (1) | AU2011274355B2 (pl) |
| CA (1) | CA2804174A1 (pl) |
| CY (1) | CY1120057T1 (pl) |
| DK (1) | DK2801625T3 (pl) |
| EA (1) | EA024450B1 (pl) |
| ES (1) | ES2664083T3 (pl) |
| HR (1) | HRP20180193T1 (pl) |
| HU (1) | HUE035574T2 (pl) |
| IL (2) | IL278149B2 (pl) |
| LT (1) | LT2801625T (pl) |
| NZ (3) | NZ605709A (pl) |
| PL (1) | PL2801625T3 (pl) |
| SI (1) | SI2801625T1 (pl) |
| UA (1) | UA116615C2 (pl) |
| WO (1) | WO2012003462A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2255184T3 (pl) | 2008-02-28 | 2013-12-31 | Univ Virginia Patent Foundation | Gen transportera serotoniny i leczenie alkoholizmu |
| PL2801625T3 (pl) | 2010-07-02 | 2018-06-29 | University Of Virginia Patent Foundation | Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków |
| EP3045173A3 (en) | 2011-09-09 | 2016-09-14 | The University of Virginia Patent Foundation | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
| WO2013138811A1 (en) * | 2012-03-16 | 2013-09-19 | Life Of Purpose, Llc | Niche-specific treatment infrastructure continuum |
| US11610144B2 (en) * | 2018-02-02 | 2023-03-21 | BioRealm LLC | Biosignature discovery for substance use disorder using statistical learning |
| WO2026011119A1 (en) * | 2024-07-05 | 2026-01-08 | Adial Pharmaceuticals, Inc. | Ondansetron treatment of alcohol use disorder |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA219554A (en) | 1922-06-13 | Edward A. Taft | Knot tying implement | |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5550021A (en) | 1990-02-07 | 1996-08-27 | Board Of Regents, The University Of Texas System | Allelic diagnosis of susceptibility to compulsive disorder |
| RU2075978C1 (ru) | 1994-03-21 | 1997-03-27 | Владислав Ефимович Шофер | Способ лечения больных хроническим алкоголизмом |
| EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| EP0945133A1 (en) | 1998-03-26 | 1999-09-29 | Lipha | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator |
| US6200604B1 (en) | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US20040167164A1 (en) | 1998-05-05 | 2004-08-26 | Jose Pozuelo | Compositions and methods for treating particular chemical addictions and mental illnesses |
| US6287765B1 (en) | 1998-05-20 | 2001-09-11 | Molecular Machines, Inc. | Methods for detecting and identifying single molecules |
| SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
| CA2362533A1 (en) | 1999-02-22 | 2000-08-31 | Variagenics, Inc. | Gene sequence variations with utility in determining the treatment of disease |
| ATE294577T1 (de) | 1999-02-24 | 2005-05-15 | Univ Cincinnati | Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen |
| WO2002026118A2 (en) | 2000-09-29 | 2002-04-04 | New Health Sciences, Inc. | Systems and methods for assessing vascular effects of a treatment |
| US7122308B2 (en) | 2001-02-16 | 2006-10-17 | Centre For Addiction And Mental Health | Detection of antidepressant induced mania |
| US7033771B2 (en) | 2001-05-08 | 2006-04-25 | Takeda Pharmaceutical Company Limited | Use of insulin response modulators in the treatment of diabetes and insulin resistance |
| EP1262196A3 (en) | 2001-05-23 | 2002-12-18 | Pfizer Products Inc. | Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence |
| EP1423116A1 (en) | 2001-08-14 | 2004-06-02 | Biotie Therapies Corp. | Method of treating alcoholism or alcohol abuse |
| WO2003018843A1 (en) | 2001-08-21 | 2003-03-06 | Smithkline Beecham Corporation | Gene polymorphisms and response to treatment |
| US20060173064A1 (en) | 2001-08-24 | 2006-08-03 | Lippa Arnold S | (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders |
| AU2002348135A1 (en) | 2001-10-31 | 2003-05-12 | Recovery Pharmaceuticals, Inc. | Methods for the treatment of addiction |
| AU2003240253A1 (en) * | 2002-05-15 | 2003-12-02 | Epidauros Biotechnologie Ag | Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications |
| WO2003100091A1 (en) * | 2002-05-24 | 2003-12-04 | Epidauros Biotechnologie Ag | Means and methods for improved treatment using 'setrones' |
| AT414215B (de) | 2003-02-12 | 2006-10-15 | Peter Ziger | Anlage zur plasmaprozessierung |
| HUE034290T2 (en) | 2003-04-29 | 2018-02-28 | Orexigen Therapeutics Inc | Preparations containing opioid antagonist and bupropion to affect weight loss |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| US7163969B2 (en) | 2003-10-14 | 2007-01-16 | Stockhausen, Inc. | Superabsorbent polymer aqueous paste and coating |
| US20050245461A1 (en) | 2004-03-19 | 2005-11-03 | Elliot Ehrich | Methods for treating alcoholism |
| WO2007009691A2 (en) | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Combination of substituted pyrazolines and anti -addictive agent |
| WO2007039123A2 (en) | 2005-09-22 | 2007-04-12 | Smithkline Beecham Corporation | Combination therapy comprising an nk-3 antagonist and an antipsychotic agent |
| CA2623072A1 (en) | 2005-09-26 | 2007-04-05 | Avigen, Inc. | Use of ibudilast for treating drug and behavioral addictions |
| US20070196841A1 (en) * | 2006-01-20 | 2007-08-23 | Gualberto Ruano | Physiogenomic method for predicting response to diet |
| US8026059B2 (en) | 2006-02-15 | 2011-09-27 | The Regents Of The University Of California | Treatment response in generalized social phobia |
| US20070292880A1 (en) | 2006-05-05 | 2007-12-20 | Robert Philibert | Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome |
| US20080004260A1 (en) | 2006-06-29 | 2008-01-03 | Transcept Pharmaceuticals, Inc. | Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions |
| US7645750B2 (en) * | 2006-12-13 | 2010-01-12 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Method of treating symptoms of hormonal variations |
| JP2010513569A (ja) | 2006-12-19 | 2010-04-30 | ユニバーシティ オブ バージニア パテント ファウンデーション | アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果 |
| US20100076006A1 (en) | 2007-01-31 | 2010-03-25 | University Of Virginia Patent Foundation | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders |
| US20080228700A1 (en) | 2007-03-16 | 2008-09-18 | Expanse Networks, Inc. | Attribute Combination Discovery |
| US20100266692A1 (en) | 2007-07-13 | 2010-10-21 | Corey Jay Bloom | Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer |
| US20110264374A1 (en) | 2007-08-21 | 2011-10-27 | University Of Virginia Patent Foundation | Method, Computer Program Product and System for Individual Assessment of Alcohol Sensitivity |
| WO2009029308A1 (en) | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| PL2255184T3 (pl) | 2008-02-28 | 2013-12-31 | Univ Virginia Patent Foundation | Gen transportera serotoniny i leczenie alkoholizmu |
| US20090269773A1 (en) | 2008-04-29 | 2009-10-29 | Nodality, Inc. A Delaware Corporation | Methods of determining the health status of an individual |
| EP2425013A1 (en) | 2009-05-01 | 2012-03-07 | University Of Virginia Patent Foundation | Serotonin transporter gene and treatment of alcoholism |
| PL2801625T3 (pl) | 2010-07-02 | 2018-06-29 | University Of Virginia Patent Foundation | Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków |
| EP3045173A3 (en) | 2011-09-09 | 2016-09-14 | The University of Virginia Patent Foundation | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
| US10997121B1 (en) | 2020-07-17 | 2021-05-04 | Snowflake Inc. | Attachable-and-detachable database sessions |
-
2011
- 2011-07-01 PL PL14173142T patent/PL2801625T3/pl unknown
- 2011-07-01 ES ES14173142.2T patent/ES2664083T3/es active Active
- 2011-07-01 NZ NZ605709A patent/NZ605709A/en unknown
- 2011-07-01 SI SI201131412T patent/SI2801625T1/en unknown
- 2011-07-01 AU AU2011274355A patent/AU2011274355B2/en active Active
- 2011-07-01 WO PCT/US2011/042823 patent/WO2012003462A1/en not_active Ceased
- 2011-07-01 EA EA201390017A patent/EA024450B1/ru unknown
- 2011-07-01 NZ NZ621356A patent/NZ621356A/en unknown
- 2011-07-01 LT LTEP14173142.2T patent/LT2801625T/lt unknown
- 2011-07-01 IL IL278149A patent/IL278149B2/en unknown
- 2011-07-01 CA CA2804174A patent/CA2804174A1/en not_active Abandoned
- 2011-07-01 DK DK14173142.2T patent/DK2801625T3/en active
- 2011-07-01 HU HUE14173142A patent/HUE035574T2/en unknown
- 2011-07-01 EP EP11801503.1A patent/EP2588630A4/en not_active Withdrawn
- 2011-07-01 UA UAA201300520A patent/UA116615C2/uk unknown
- 2011-07-01 EP EP14173142.2A patent/EP2801625B1/en active Active
- 2011-07-01 NZ NZ621352A patent/NZ621352A/en unknown
-
2012
- 2012-08-20 US US13/589,603 patent/US8753815B2/en active Active
-
2014
- 2014-04-30 US US14/266,313 patent/US9539242B2/en active Active
-
2017
- 2017-01-03 US US15/397,076 patent/US10603307B2/en active Active
-
2018
- 2018-02-01 HR HRP20180193TT patent/HRP20180193T1/hr unknown
- 2018-02-01 CY CY20181100127T patent/CY1120057T1/el unknown
- 2018-11-07 IL IL262874A patent/IL262874B/en active IP Right Grant
-
2020
- 2020-02-06 US US16/784,051 patent/US11324723B2/en active Active
- 2020-10-02 US US17/061,749 patent/US11116753B2/en active Active
-
2022
- 2022-04-18 US US17/659,641 patent/US12150931B2/en active Active
-
2023
- 2023-02-03 US US18/164,175 patent/US12226401B2/en active Active
- 2023-03-23 US US18/188,755 patent/US11957664B2/en active Active
-
2024
- 2024-03-29 US US18/622,489 patent/US12274692B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278149A (en) | A molecular genetic approach to the treatment and diagnosis of alcohol and drug dependence | |
| IL273107B (en) | Pharmaceutical preparations of human rpe cells and their use | |
| EP2413917A4 (en) | DRUG DELIVERY SYSTEM AND METHODS OF USING THE SAME | |
| ZA201301601B (en) | Treatment of diseases | |
| EP2521553A4 (en) | METHODS AND COMPOSITIONS FOR THE DEVELOPMENT OF TARGETED MEDICAMENTS | |
| EP2531908A4 (en) | SEARCH REQUEST PROCESSING | |
| GB201302653D0 (en) | Pharmaceutical compositions and methods of treatment | |
| GB2496794B (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| ZA201300218B (en) | Treatment of blood cancer | |
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| GB201104473D0 (en) | Improved pharmaceutical compositions and methods of delivery | |
| PL2464342T3 (pl) | Formulacje farmaceutyczne do zapobiegania niewłaściwemu użyciu leków medycznych | |
| EP2585828A4 (en) | METHOD FOR THE TREATMENT OF PATIENTS WITH IMMUNE SYSTEM DISEASES | |
| EP2626071A4 (en) | APPLICATIONS OF ARCTIGENIN FOR THE FORMULATION OF MEDICAMENTS FOR THE PROPHYLAXIS OR THE TREATMENT OF DISEASES RELATED TO THE REDUCTION OF RED BLOOD BODIES | |
| PL2582366T3 (pl) | Kombinacja farmaceutyczna do leczenia bólu | |
| PL2613798T3 (pl) | Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów | |
| ITTO20110631A1 (it) | Composizione farmaceutica di combinazione e metodi per trattare patologie del sistema genitourinario | |
| ZA201502332B (en) | Medicinal treatment of dermal diseases in companion animals with norketotifen | |
| SG11201401038VA (en) | Isolating and therapeutic use of perivascular medicinal cells | |
| EP2744512A4 (en) | Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis | |
| EP2531202A4 (en) | USE OF HEPARIN-BASED ORAL PREPARATIONS FOR TREATING DISEASES AND DISEASES OF THE URINARY TRACT | |
| PT2632885T (pt) | Compostos carboxilatos de fenilcetona e usos farmacêuticos destes | |
| EP2650292A4 (en) | THIAZOLAMINE DERIVATIVE AND ITS PHARMACEUTICAL APPLICATIONS FOR SMALL RNA VIRAL INFECTIONS | |
| HK1184504A (en) | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence | |
| IL222690A0 (en) | Treatment of autoimmune diseases |